PhaseBio Pharmaceuticals, Inc. Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases
6/18/2013 9:30:58 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MALVERN, Pa.--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company focused on diabetes and cardiovascular diseases, today announced the successful completion of a Phase 1 trial of Vasomera™ (PB1046), the first once-weekly investigational, VPAC2 selective receptor agonist for the treatment of cardiopulmonary diseases. This multi-center, randomized, double-blind, placebo-controlled trial demonstrated the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) response of single ascending subcutaneous (SC) doses of Vasomera in 40 patients. Trial results showed PD activity that was supportive of a once-weekly dosing regimen that could allow for chronic use in a home setting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by